Holen Sie sich die Stockscreener-App
35.27
3.58%
1.22
Vorhandelsmarkt:
34.01
-1.26
-3.57%
Schlusskurs vom Vortag:
$34.05
Offen:
$34.14
24-Stunden-Volumen:
8.95M
Relative Volume:
2.00
Marktkapitalisierung:
$14.22B
Einnahmen:
$2.26B
Nettoeinkommen (Verlust:
$1.09B
KGV:
15.05
EPS:
2.3431
Netto-Cashflow:
$2.70B
1W Leistung:
+4.50%
1M Leistung:
+5.76%
6M Leistung:
+39.90%
1J Leistung:
+29.67%
1-Tages-Spanne:
$34.14
$35.37
1-Wochen-Bereich:
$33.37
$35.37
52-Wochen-Spanne:
$24.05
$35.37
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Vergleichen Sie RPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
35.27 | 14.22B | 2.26B | 1.09B | 2.70B | 2.3431 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.06 | 113.97B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.84 | 52.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
304.67 | 40.16B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
586.76 | 35.45B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
276.53 | 27.94B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Pallas Capital Advisors LLC Purchases 8,113 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Reaches New 52-Week HighHere's Why - MarketBeat
Royalty Pharma stock hits 52-week high at $34.33 amid robust growth - Investing.com
Handelsbanken Fonder AB Sells 26,695 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Wedge Capital Management L L P NC Buys Shares of 1,014,799 Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com Nigeria
RPRX Q1 Earnings Call: Flat Revenue, Portfolio Expansion, and Capital Return Initiatives - Yahoo Finance
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Ameriprise Financial Inc. - MarketBeat
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Royalty Pharma to Share Strategic Updates at Goldman Sachs Healthcare Conference 2025 - Stock Titan
(RPRX) Technical Data - news.stocktradersdaily.com
Mackenzie Financial Corp Increases Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
33,531 Shares in Royalty Pharma plc (NASDAQ:RPRX) Acquired by 111 Capital - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) On An Uptrend: Could Fundamentals Be Driving The Stock? - Yahoo Finance
150,344 Shares in Royalty Pharma plc (NASDAQ:RPRX) Acquired by Lansforsakringar Fondforvaltning AB publ - MarketBeat
California State Teachers Retirement System Purchases 104,338 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Stock Position Trimmed by Tidal Investments LLC - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 350,315 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
GF Fund Management CO. LTD. Invests $238,000 in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Squarepoint Ops LLC Lowers Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Stock Holdings Lifted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - MarketBeat
Janus Henderson Group PLC Decreases Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
University of Texas Texas AM Investment Management Co. Purchases New Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Nuveen Asset Management LLC Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Quantinno Capital Management LP Grows Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
State of Wyoming Has $385,000 Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Captrust Financial Advisors Lowers Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Two Sigma Investments LP Has $61.74 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Worldquant Millennium Advisors LLC Has $15.57 Million Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Point72 Asset Management L.P. - MarketBeat
USS Investment Management Ltd Lowers Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
How to Take Advantage of moves in (RPRX) - news.stocktradersdaily.com
Raiffeisen Bank International AG Makes New $506,000 Investment in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Two Sigma Advisers LP Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma - insights.citeline.com
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Man Group plc - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Stock Rating Lowered by StockNews.com - Defense World
Royalty Pharma plc (NASDAQ:RPRX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.96%
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):